twist bioscience corp - TWST
TWST
Close Chg Chg %
140.80 10.62 7.54%
Closed Market
151.42
+10.62 (7.54%)
Volume: 2.08M
Last Updated:
Aug 25, 2026, 4:00 PM EDT
Company Overview: twist bioscience corp - TWST
TWST Key Data
| Open $145.73 | Day Range 141.41 - 154.96 |
| 52 Week Range 23.30 - 154.96 | Market Cap $9.58B |
| Shares Outstanding 65.83M | Public Float 63.54M |
| Beta 2.14 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$2.22 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.80M |
TWST Performance
| 1 Week | 4.00% | ||
| 1 Month | 67.74% | ||
| 3 Months | 149.99% | ||
| 1 Year | 461.44% | ||
| 5 Years | 35.69% |
TWST Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
10
Full Ratings ➔
About twist bioscience corp - TWST
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.
TWST At a Glance
Twist Bioscience Corp.
681 Gateway Boulevard
San Francisco, California 94080
| Phone | 1-800-719-0671 | Revenue | 376.57M | |
| Industry | Biotechnology | Net Income | -77,670,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 20.321% | |
| Fiscal Year-end | 09 / 2026 | Employees | 979 | |
| View SEC Filings |
TWST Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.469 |
| Price to Book Ratio | 3.607 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -13.699 |
| Enterprise Value to Sales | 4.053 |
| Total Debt to Enterprise Value | 0.05 |
TWST Efficiency
| Revenue/Employee | 384,649.642 |
| Income Per Employee | -79,336.057 |
| Receivables Turnover | 6.57 |
| Total Asset Turnover | 0.60 |
TWST Liquidity
| Current Ratio | 3.643 |
| Quick Ratio | 3.333 |
| Cash Ratio | 2.543 |
TWST Profitability
| Gross Margin | 50.721 |
| Operating Margin | -36.184 |
| Pretax Margin | -20.435 |
| Net Margin | -20.626 |
| Return on Assets | -12.366 |
| Return on Equity | -16.427 |
| Return on Total Capital | -14.16 |
| Return on Invested Capital | -14.415 |
TWST Capital Structure
| Total Debt to Total Equity | 15.979 |
| Total Debt to Total Capital | 13.777 |
| Total Debt to Total Assets | 11.774 |
| Long-Term Debt to Equity | 13.056 |
| Long-Term Debt to Total Capital | 11.257 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Twist Bioscience Corp - TWST
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 203.56M | 245.11M | 312.97M | 376.57M | |
Sales Growth
| +53.83% | +20.41% | +27.69% | +20.32% | |
Cost of Goods Sold (COGS) incl D&A
| 119.33M | 155.38M | 179.63M | 185.57M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 36.64M | 29.31M | 31.43M | 24.85M | |
Depreciation
| 31.74M | 24.01M | 27.33M | 23.75M | |
Amortization of Intangibles
| 4.90M | 5.30M | 4.10M | 1.10M | |
COGS Growth
| +48.02% | +30.21% | +15.60% | +3.31% | |
Gross Income
| 84.23M | 89.73M | 133.35M | 191.00M | |
Gross Income Growth
| +62.89% | +6.52% | +48.61% | +43.23% | |
Gross Profit Margin
| +41.38% | +36.61% | +42.61% | +50.72% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 333.26M | 296.63M | 309.25M | 327.26M | |
Research & Development
| 120.31M | 106.89M | 90.85M | 80.28M | |
Other SG&A
| 212.95M | 189.74M | 218.40M | 246.98M | |
SGA Growth
| +62.59% | -10.99% | +4.25% | +5.82% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | (14.24M) | 10.26M | 44.93M | |
EBIT after Unusual Expense
| (234.78M) | (217.16M) | (220.83M) | (136.26M) | |
Non Operating Income/Expense
| 6.58M | 13.70M | 12.69M | 59.31M | |
Non-Operating Interest Income
| 3.06M | 14.37M | 15.34M | 11.36M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | 80.00K | 5.00K | 29.00K | |
Interest Expense Growth
| -78.20% | -93.75% | +480.00% | -100.00% | |
Gross Interest Expense
| - | 80.00K | 5.00K | 29.00K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (228.27M) | (203.47M) | (208.17M) | (76.95M) | |
Pretax Income Growth
| -48.20% | +10.87% | -2.31% | +63.03% | |
Pretax Margin
| -112.14% | -83.01% | -66.51% | -20.43% | |
Income Tax
| (10.41M) | 1.15M | 560.00K | 719.00K | |
Income Tax - Current - Domestic
| (1.00K) | 9.00K | 20.00K | 27.00K | |
Income Tax - Current - Foreign
| 767.00K | 1.14M | 540.00K | 692.00K | |
Income Tax - Deferred - Domestic
| - | - | - | (11.18M) | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (217.86M) | (204.62M) | (208.73M) | (77.67M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (217.86M) | (204.62M) | (208.73M) | (77.67M) | |
Net Income Growth
| -43.24% | +6.08% | -2.01% | +62.79% | |
Net Margin Growth
| -107.02% | -83.48% | -66.69% | -20.63% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (217.86M) | (204.62M) | (208.73M) | (77.67M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (217.86M) | (204.62M) | (208.73M) | (77.67M) | |
EPS (Basic)
| -4.0431 | -3.597 | -3.5977 | -1.2987 | |
EPS (Basic) Growth
| -28.26% | +11.03% | -0.02% | +63.90% | |
Basic Shares Outstanding
| 53.88M | 56.88M | 58.02M | 59.81M | |
EPS (Diluted)
| -4.0431 | -3.597 | -3.5977 | -1.2987 | |
EPS (Diluted) Growth
| -28.26% | +11.03% | -0.02% | +63.90% | |
Diluted Shares Outstanding
| 53.88M | 56.88M | 58.02M | 59.81M | |
EBITDA
| (212.38M) | (177.59M) | (144.47M) | (111.41M) | |
EBITDA Growth
| -50.34% | +16.38% | +18.65% | +22.89% | |
EBITDA Margin
| -104.33% | -72.45% | -46.16% | -29.58% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 104.00 | |
| Number of Ratings | 10 | Current Quarters Estimate | -0.395 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | -2.16 | |
| Last Quarter’s Earnings | -0.56 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.30 | Next Fiscal Year Estimate | -1.402 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 7 | 7 | 8 |
| Mean Estimate | -0.39 | -0.40 | -2.16 | -1.40 |
| High Estimates | -0.35 | -0.36 | -2.04 | -1.20 |
| Low Estimate | -0.47 | -0.50 | -2.24 | -1.79 |
| Coefficient of Variance | -10.59 | -11.81 | -2.99 | -15.58 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 7 | 6 |
| OVERWEIGHT | 2 | 2 | 2 |
| HOLD | 1 | 1 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Twist Bioscience Corp - TWST
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Twist Bioscience Corp - TWST
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Aug 17, 2026 | Katryn Shineman Blake Director | 17,208 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $122.88 per share | 2,114,519.04 |
| Aug 17, 2026 | Emily Marine Leproust Chief Executive Officer; Director | 133,269 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 17, 2026 | Emily Marine Leproust Chief Executive Officer; Director | 818,938 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $125.08 per share | 102,432,765.04 |
| Aug 17, 2026 | Emily Marine Leproust Chief Executive Officer; Director | 838,890 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $26.66 per share | 22,364,807.40 |
| Jul 14, 2026 | Adam Laponis Chief Financial Officer | 110,276 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $94.33 per share | 10,402,335.08 |
| May 27, 2026 | Robert F. Werner Chief Accounting Officer | 48,986 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $53.26 per share | 2,608,994.36 |
| May 7, 2026 | Patrick J. Finn President and COO | 278,964 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $57.15 per share | 15,942,792.60 |
| May 7, 2026 | Paula Green SVP of Human Resources | 122,988 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $57.15 per share | 7,028,764.20 |
| May 7, 2026 | Dennis Hohn Cho See Remarks | 135,941 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $57.15 per share | 7,769,028.15 |
| Apr 30, 2026 | Melissa A. Starovasnik Director | 25,222 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $61.83 per share | 1,559,476.26 |
| Feb 20, 2026 | Patrick J. Finn President and COO | 356,755 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $26.66 per share | 9,511,088.30 |
| Feb 20, 2026 | Patrick J. Finn President and COO | 334,897 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.32 per share | 16,852,017.04 |
| Feb 20, 2026 | Patrick J. Finn President and COO | 318,281 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $51.42 per share | 16,366,009.02 |
| Feb 20, 2026 | Patrick J. Finn President and COO | 291,329 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $52.69 per share | 15,350,125.01 |
| Feb 20, 2026 | Patrick J. Finn President and COO | 287,788 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $53.11 per share | 15,284,420.68 |
| Feb 20, 2026 | Patrick J. Finn President and COO | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Patrick J. Finn President and COO | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 6, 2026 | Robert F. Werner Chief Accounting Officer | 58,738 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $45.65 per share | 2,681,389.70 |
| Nov 21, 2025 | Jan Johannessen Director | 14,859 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.77 per share | 368,057.43 |